quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:03:09·8d
SECFiling
KALA BIO Inc. logo

SEC Form 10-K filed by KALA BIO Inc.

KALA· KALA BIO Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • KALA
    KALA BIO Inc.
    Health Care

Recent analyst ratings

  • Sep 30UpdateMizuho$1.50
  • Sep 29UpdateH.C. Wainwright-
  • Sep 29UpdateLadenburg Thalmann-
  • Sep 8UpdateMizuho$30.00
  • Jul 11UpdateLadenburg Thalmann$12.00
  • Mar 30UpdateJP Morgan-

Related

  • PR2d
    Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
  • PR22d
    Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
  • SEC23d
    SEC Form NT 10-K filed by KALA BIO Inc.
  • PR24d
    KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
  • PR36d
    Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
  • SEC37d
    SEC Form D filed by KALA BIO Inc.
  • SEC37d
    SEC Form 144 filed by KALA BIO Inc.
  • SEC42d
    SEC Form 144 filed by KALA BIO Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022